tirzepatide cardiovascular outcomes trial results july 2025 in Diabetes: New Evidence From Trials Frontiers | Tirzepatide vs. semaglutide

While public statements do not instantly change federal law, this potential regulatory shift has sparked widespread excitement about the future of physician-led peptide therapies

Krbling M, Drach J, Champlin RE, Engel H, Kleine HD, Berenson R, Deisseroth A, Andreeff M

With an increasing number of similar GLP-1 drugs now being used in clinical practice, for conditions ranging from type 2 diabetes and obesity to kidney disease, our findings highlight the potential for these existing drugs to be repurposed to treat the risk of no-reflow in heart attack patients, offering a potentially life-saving solution, said University College London Professor David Atwell

Aumento de peso Recuperar peso es un efecto secundario que las personas experimentan cuando dejan de tomar un GLP-1

Clinical trial data from the SURMOUNT-5 trial shows tirzepatide produced approximately 47 percent more weight loss than a semaglutide comparator over 72 weeks (average of 50 pounds versus 33 pounds)

PlexusDx has no commercial relationship with Henry Meds or its parent company, and no affiliate links or compensation are involved